Is ESSA Pharma a good dividend stock?

ESSA Pharma (TSE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include OPKO Health (OPK) , TherapeuticsMD (TXMD) , bluebird bio (BLUE) , Gray Television (GTN) , Allergan (AGN) , Cardiome Pharma (CRME) , CEMEX (CX) , Groupon (GRPN) , Horizon Therapeutics Public (HZNP) and Tandem Diabetes Care (TNDM) .

How do I buy shares of ESSA Pharma?

Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:EPI

ESSA Pharma (EPI) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free EPI Stock Alerts

Today's Range: N/A
50-Day Range: C$0.32
▼
C$0.32
52-Week Range: N/A

Volume: 4,700 shs
Average Volume: 68,239 shs
Market Capitalization: C$9.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get ESSA Pharma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About ESSA Pharma

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

EPI Stock News Headlines

April 7, 2024 | uk.investing.com

ESSA Pharma Inc (EPIX)

January 30, 2024 | realmoney.thestreet.com

Essa Pharma initiated with bullish view at JonesResearch, here's why

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 26, 2024 | finance.yahoo.com

EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…

January 26, 2024 | msn.com

What's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?

January 25, 2024 | finanznachrichten.de

ESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

January 25, 2024 | finance.yahoo.com

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

December 12, 2023 | finance.yahoo.com

ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

November 23, 2023 | finance.yahoo.com

Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares

November 7, 2023 | seekingalpha.com

ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance

October 24, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)

October 6, 2023 | benzinga.com

Prostate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

September 20, 2023 | seekingalpha.com

ESSA Pharma files for $200M mixed shelf offering - filing

August 9, 2023 | msn.com

Oppenheimer Reiterates Essa Pharma (EPIX) Outperform Recommendation

April 4, 2023 | msn.com

Why are EpiPens still so expensive?

February 13, 2023 | finance.yahoo.com

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

December 19, 2022 | finance.yahoo.com

EPIX: Advancing Multiple Clinical Trials in 2023…

November 16, 2022 | seekingalpha.com

ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer

October 31, 2022 | marketwatch.com

Essa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trials

October 31, 2022 | seekingalpha.com

ESSA drops 26% as Johnson & Johnson ends trial enrollment for lead asset

October 26, 2022 | finance.yahoo.com

ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium

October 26, 2022 | marketwatch.com

ESSA Pharma Surges 152% on Study Results for Lead Drug Candidate

October 26, 2022 | finance.yahoo.com

Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium

October 26, 2022 | seekingalpha.com

ESSA Pharma jumps 91% on Phase 1/2 data for prostate cancer therapy

August 10, 2022 | finance.yahoo.com

EPIX: Multiple Ongoing Studies of EPI-7386…

June 28, 2022 | finance.yahoo.com

ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer

See More Headlines

Receive EPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: TSE:EPI
CUSIP: N/A
CIK: N/A
Web: essapharmaceuticals.com
Phone: +1-778-3310962
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 29,102,000
Free Float: N/A
Market Cap: C$9.31 million
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Richard M. Glickman LL.D. (Age 57)
Chairman of the Board
David Ross Parkinson M.D. (Age 67)
President, Chief Executive Officer, Director
David Wood (Age 57)
Chief Financial Officer
Peter Virsik
Chief Operating Officer, Executive Vice President
Raymond L. Andersen (Age 67)
Chief Technology Officer, Director
Marianne D. Sadar (Age 53)
Chief Scientific Officer, Director
Frank Perabo (Age 50)
Chief Medical Officer
Franklin M. Berger (Age 67)
Director
Scott Requadt J.D.
Director
Gary Sollis (Age 61)
Director

Insiders

EPI Stock Analysis - Frequently Asked Questions

Is ESSA Pharma a good dividend stock?: ESSA Pharma (TSE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%.
What other stocks do shareholders of ESSA Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), bluebird bio (BLUE), Gray Television (GTN), Allergan (AGN), Cardiome Pharma (CRME), CEMEX (CX), Groupon (GRPN), Horizon Therapeutics Public (HZNP) and Tandem Diabetes Care (TNDM).
How do I buy shares of ESSA Pharma?: Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:EPI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ESSA Pharma (EPI) Stock Price, News & Analysis

About ESSA Pharma

EPI Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Insiders

EPI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info